Mylan launches Hulio™ (biosimilar adalimumab) in markets across Europe
Mylan announced that it has initiated the commercial launch of Hulio™, a biosimilar to AbbVie's Humira® (adalimumab), across major markets in Europe. The product, which is approved for all adalimumab indications, will be available to patients as soon as possible. October 19, 2018